Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments
May 12 2021 - 8:30AM
Business Wire
- ISS ESG Corporate Rating uses comprehensive
research and data to allow institutional investors to identify
Environmental, Social and Governance (ESG) risks and seize
investment opportunities
- Inaugural year of Prime status for Arena,
following the Company’s 2021 ESG Report launch
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it
has been designated Prime in the ISS ESG Corporate Rating,
effective as of May 4, 2021. Companies are classified as Prime when
their ESG performance exceeds the threshold criteria for companies
in its sector, meaning they fulfill ambitious absolute performance
requirements.
The ISS ESG Corporate Rating sets the industry standard for
sustainable investing and is used by international institutional
investors and financial service companies to inform their
decisions. According to this rating, Arena tradeable bonds and
shares will now qualify for responsible investment.
“This rating reinforces our far-reaching efforts to build a
vibrant, sustainable enterprise with the ultimate goal of
delivering our important medicines to patients who need them,” said
Laurie Stelzer, Chief Financial Officer of Arena Pharmaceuticals.
“Our management team, our employees, and our Board of Directors all
embrace a long-term commitment to ESG principles for the betterment
of our company and the communities we are working in. We are proud
to be recognized as not only a sustainable company, but also a
sustainable investment.”
The Prime status follows the release of Arena’s second annual
ESG report in April 2021, outlining the Company’s long-term
commitment to the betterment of society, focusing on patients,
employees, the community, the environment, and shareholders.
For more information on the ISS ESG Corporate Rating, please
visit: issgovernance.com/esg/ratings/.
View the full 2021 Arena ESG Report on the Arena Investors page:
https://invest.arenapharm.com/.
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a singular purpose –
deliver important medicines to patients.
In a rapidly changing global market, we work with a sense of
urgency every day to understand the needs of all our stakeholders,
identify bold, sometimes disruptive, ideas to get medicines to
patients, and relentlessly execute until it's done.
We are developing a richly diversified portfolio of therapeutic
candidates targeting gastroenterology, dermatology and cardiology.
Our pipeline includes four investigational medicines in eight
indications and eleven ongoing or planned clinical trials. To fuel
our growth, we are unlocking the value of our historical GPCR
research with a sustainable discovery engine for broad portfolio
expansion.
ARENA - Care More. Act Differently.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements may be identified by words such as
“will,” “efforts to,” “long-term,” “commitment,” “purpose,”
“targeting,” and “planned,” and include, without limitation,
statements about Arena's ESG initiatives, purpose, work,
understanding, ideas, execution, portfolio, and discovery engine.
For such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Arena's expectations. Factors that could
cause actual results to differ materially from the forward-looking
statements include those disclosed in Arena's filings with the
Securities and Exchange Commission (SEC), including but not limited
to Arena’s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2021, which was filed with the SEC on May 5, 2021. These
forward-looking statements represent Arena's judgment as of the
time of this release. Arena disclaims any intent or obligation to
update these forward-looking statements, other than as may be
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210512005333/en/
Corporate Contact: Patrick Malloy Arena Pharmaceuticals,
Inc. Vice President, Investor Relations & Corporate
Communications pmalloy@arenapharm.com 847.987.4878
Arena Media Contact: IR@arenapharm.com 858.453.7200
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Apr 2023 to Apr 2024